Old Web
English
Sign In
Acemap
>
authorDetail
>
Mathias J. Rummel
Mathias J. Rummel
Rituximab
Medicine
Pathology
Lymphoma
Bendamustine
4
Papers
9
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
2014
Journal of Clinical Oncology
John P. Leonard
Pier Luigi Zinzani
Wojciech Jurczak
Mathias J. Rummel
Gilles Salles
Eva Kimby
Hendrik-Tobias Arkenau
Andrew Davies
David Michael Johnson
Shelley Evans
Roger Dansey
Wayne Godfrey
Brad S. Kahl
Show All
Source
Cite
Save
Citations (9)
German Experience with Bendamustine in B-cell Lymphoid Malignancies
2009
Clinical advances in hematology & oncology
Mathias J. Rummel
Show All
Source
Cite
Save
Citations (0)
Optimal Dosing and Scheduling of Bendamustine
2009
Clinical advances in hematology & oncology
Mathias J. Rummel
Show All
Source
Cite
Save
Citations (0)
Rituximab for the therapy of non-Hodgkins lymphoma
2007
Onkologe
Mathias J. Rummel
Show All
Source
Cite
Save
Citations (0)
1